How long do I usually need to take Axitinib?

Axitinib (Axitinib) is a small molecule tyrosine kinase inhibitor (TKI), mainly used to treat advanced renal cell carcinoma, especially in patients after failure of first-line treatment (such as sorafenib or sunitinib). Its mechanism of action is to block tumor angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR), thereby limiting tumor growth and spread. As an oral targeted drug, axitinib treatment is usually continuous and does not have a fixed course of treatment.

The duration of taking axitinib mainly depends on the patient's tolerance to the drug, therapeutic response, and whether there are obvious side effects or drug resistance. In clinical practice, as long as the drug can control the disease and is well tolerated by the patient, doctors usually recommend that the patient continue to take it until disease progression or intolerable side effects occur. According to relevant studies and actual cases, some patients can continue to take axitinib for more than a year or even longer.

It should be noted that during the course of taking it, patients need to undergo regular imaging examinations (such asCT, MRI) to evaluate tumor changes, and at the same time monitor liver and kidney function, blood pressure, thyroid function and other indicators in order to adjust the dosage or deal with adverse reactions in a timely manner. If the tumor shrinks or stabilizes during treatment, but is accompanied by severe side effects, the doctor may recommend temporarily stopping the drug or reducing the dose until the patient recovers before continuing treatment.

In summary, axitinib is not a short-term drug, but a targeted therapy drug that needs to be taken long-term to inhibit tumor progression. Most patients will continue to take it for months or even years under the guidance of a doctor. Therefore, patients need to be prepared to take the medicine for a long time and closely cooperate with the doctor for regular review to ensure the safety and effectiveness of the treatment. At the same time, patients can also discuss with their doctors whether combination immunotherapy or changing treatment options is suitable to further extend the time of disease control.

Reference materials:https://en.wikipedia.org/wiki/Axitinib